Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Innovation Council · Running

PARAGON NOVEL VACCINE Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR)

Coordinator
Immunethep, Portugal
Runs
1 January 2023 to 30 November 2026
Status
Running
EU funding
€2.5m
Total cost
€7.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190152193

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection.

PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.

Topics

Who is involved

OrganisationCityCountryRole
ImmunethepCantanhedePortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI